Full text is available at the source.
Sodium‐glucose co‐transporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors on major liver outcomes in metabolic dysfunction‐associated steatotic liver disease
Comparing two diabetes drugs on major liver problems in fatty liver disease linked to metabolism
AI simplified
Abstract
Among 44,651 patients, the incidence rate of major liver outcomes (MLO) was 3.8 per 1000 person-years for those on sodium-glucose co-transporter-2 inhibitors (SGLT2is) and 3.9 per 1000 person-years for those on dipeptidyl peptidase-4 inhibitors (DPP4is).
- SGLT2i initiation was associated with an adjusted hazard ratio (aHR) of 0.82 for MLO diagnosis compared to DPP4is.
- There was no significant association between SGLT2is and the risk of cirrhosis (aHR: 0.77) or hepatocellular carcinoma (aHR: 0.99).
- Subgroup and sensitivity analyses did not reveal significant differences in outcomes between the two medication groups.
AI simplified